[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349857-105":59,"doc-detail-349857-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-transcriptome-profiling-of-sporadic-medullary-thyroid-carcinomas-data-descriptor-background-summary","Comprehensive transcriptome Profiling of Sporadic Medullary Thyroid Carcinomas - Data descriptor - Background & Summary","","Medullary thyroid carcinoma (MTC) is a rare neuroendocrine cancer with limited transcriptomic characterization and unclear molecular mechanisms driving progression. This study performs transcriptome profiling on 72 MTC specimens from patients with diverse genetic backgrounds. The dataset emphasizes molecular heterogeneity across sporadic cases and supports the need for personalized treatment strategies. Clinical context highlights RET/RAS-driven biology, aggressive disease behavior, and poor survival in advanced MTC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-transcriptome-profiling-of-sporadic-medullary-thyroid-carcinomas-data-descriptor-background-summary/349857/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-transcriptome-profiling-of-sporadic-medullary-thyroid-carcinomas-data-descriptor-background-summary/349857.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this transcriptome study of sporadic MTC?","Question",{"text":112,"@type":113},"To perform transcriptome profiling on 72 MTC specimens and highlight molecular heterogeneity that may inform personalized treatment strategies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which genetic alterations are commonly found in sporadic MTC?",{"text":117,"@type":113},"Somatic mutations in RET and RAS are detected in roughly 50%–80% of sporadic cases, while other alterations such as TP53, EIF1AX, PTEN, and MET are described as rare.",{"name":119,"@type":110,"acceptedAnswer":120},"How is MTC typically diagnosed and what is its key biochemical marker?",{"text":121,"@type":113},"Diagnosis relies on serum calcitonin (CT) measurement and histological analysis, with elevated calcitonin expression serving as the main biochemical hallmark.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349857,1790167834,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificdata](www. nature.com/scientificdata)  \nOPEN  \nDATA DESCRIPTOR  \nComprehensive transcriptome Profiling of Sporadic Medullary Thyroid Carcinomas  \nDomenico Palumbo1,7, Viola Melone1,7, Luigi Palo1,2, Fabio Russo1,3, Domenico Rocco4  \n,  \nCaterina Mian5, Susi Barollo5, Simona Censi5, Loris Bertazza5, Maria Chiara Zatelli6, Alessandro Weisz1,2,3, Robertatarallo1,2,3 ✉ & Mario Vitale4 ✉  \nMedullary thyroid carcinoma (MTC) is a rare thyroid cancer arising from parafollicular C cells belonging to the heterogeneous class of neuroendocrine neoplasms. Mutations in the RET and RAS genes are detected in approximately 50% to 80% of sporadic MTCs, while other genetic alterations are relatively uncommon. Only a few transcriptomic studies of this neoplasia have been performed, and the biology and the molecular mechanisms underlying its progression remain largely unknown. In this study, we performed transcriptome profiling of a cohort comprising 72 MTC specimens from patients with different genetic backgrounds. The presented data highlighted the molecular heterogeneity of MTCsand the need for personalized treatment strategies. For this reason, the obtained profiles could offer novel perspectives into the molecular landscape of this neoplasm within the scientific community.  \nBackground & Summary  \nMedullary thyroid carcinoma (MTC) is a rare tumor that develops from the parafollicular C cells of the thyroid gland deriving from the neural crest, and it is classified as a neuroendocrine tumor. It can occur in either sporadic or familial forms. MTC, which represents 3–5% of all thyroid cancers1, typically exhibits a more aggressive behaviour, and in 22–55% of cases, is locally advanced, metastatic at diagnosis or becomes so during follow-up2. In advanced MTC, survival remains extremely poor, with reported rates of approximately 26% at 5 years and 10% at 10 years3,4. The main biochemical hallmark of this neoplasm is elevated calcitonin (CT) expression; therefore, serum CT measurement and histological analysis are considered the standard approaches for an accurate diagnosis. Most of these neoplasms (~75%) are sporadic while the remaining (~25%) arise in the context of hereditary syndromes, such as the multiple endocrine neoplasia type 2 (MEN2) and the Familial MTC 1,5. While almost the totality of hereditary MTCs are linked to the occurrence of germline activating RET gene mutations6–8, sporadic MTCs harbour RET mutations in approximately 25%-40% of cases and RAS mutations in another 10%-25%, with no overlap between the two8–10. Globally, somatic mutations in the RET and RAS genes are detected in approximately 50% to 80% of sporadic MTC cases. Although additional genetic alterations including TP53, EIF1AX, PTEN, and MET have been described, they are extremely rare, and many cases are orphan of a genetic driver8, 11.  \nRET gene encodes for a tyrosine kinase receptor protein that binds several factors, such as the glial cell-line derived neurotrophic factor (GDNF), playing a role in cell growth, migration, differentiation and survival via the RAF-MEK-ERK and PI3K-AKT-mTOR pathways 12. The oncogenic transformation ofRET can confer to the cells ligand-independent growth and resistance to the apoptotic stimuli, and it is associated with the most aggressive hereditary form of this neoplasm. Among others, the M918T mutation, occurring in nearly 70% of all cases13, is still one of the most studied and targetable; indeed this has been proved to be a negative prognostic  \n1Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, 84081, Baronissi, SA, Italy. 2Genome Research Center for Health, 84081, Baronissi, SA, Italy. 3Medical Genomics Program, Division of Oncology, AOU “S. Giovanni di Dio e Ruggi d’Aragona”, University of Salerno, Salerno, italy. 4Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salern","cbCaioAnyMvxBS2M","https://ap.wps.com/l/cbCaioAnyMvxBS2M","pdf",4354743,"English","# Background & Summary\n## Study aim and rationale\n## MTC clinical context and genetics\n## RET pathway and therapeutic context\n## Prior transcriptomic studies","[{\"question\":\"What is the main goal of this transcriptome study of sporadic MTC?\",\"answer\":\"To perform transcriptome profiling on 72 MTC specimens and highlight molecular heterogeneity that may inform personalized treatment strategies.\"},{\"question\":\"Which genetic alterations are commonly found in sporadic MTC?\",\"answer\":\"Somatic mutations in RET and RAS are detected in roughly 50%–80% of sporadic cases, while other alterations such as TP53, EIF1AX, PTEN, and MET are described as rare.\"},{\"question\":\"How is MTC typically diagnosed and what is its key biochemical marker?\",\"answer\":\"Diagnosis relies on serum calcitonin (CT) measurement and histological analysis, with elevated calcitonin expression serving as the main biochemical hallmark.\"}]","Comprehensive transcriptome Profiling of Sporadic Medullary Thyroid Carcinomas - Data descriptor - Background & Summary | PDF",1790085996,18]